Renal Cancer - Results from #5500

Malignancy rates and diagnostic performance of the Bosniak classification for the diagnosis of cystic renal lesions in computed tomography - a systematic review and meta-analysis October 25, 2016

Postoperative Outcome of Cystic Renal Cell Carcinoma Defined on Preoperative Imaging: A Retrospective Study October 24, 2016

Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma October 24, 2016

Prognostic Significance of CD24 in Clear Cell Renal Cell Carcinoma October 21, 2016

MiR-99b-5p expression and response to tyrosine kinase inhibitor treatment in clear cell renal cell carcinoma patients October 21, 2016

Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib October 20, 2016

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study October 20, 2016

Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach October 18, 2016

Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors October 18, 2016

Meta-analysis of gene expression and integrin-associated signaling pathways in papillary renal cell carcinoma subtypes October 14, 2016

Simultaneous occurrence of non-Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report October 14, 2016

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma October 13, 2016

Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma October 13, 2016

Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection October 12, 2016

Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets October 12, 2016

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors October 11, 2016

Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation October 11, 2016

Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer October 7, 2016

Cytoreductive nephrectomy for metastatic renal cell carcinoma October 7, 2016

Radical Nephrectomy With or Without Lymph Node Dissection for Nonmetastatic Renal Cell Carcinoma: A Propensity Score-based Analysis October 7, 2016

Page 276 of 456